Spread and Course of COVID-19 Infections (CoV-ETH)

Longitudinal Serological Study on the Spread and Course of COVID-19 Infections

The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.

Study Overview

• Status: Completed
• Conditions: Covid-19; Virus Disease

• Study Type: Observational
• Enrollment (Actual): 2910

Contacts and Locations

Study Locations

• Switzerland
  • Zürich, Switzerland, 8092
    • ETH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 64 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The cohort consists of initially healthy volunteers, all employees or students of ETH. Inclusion into the longitudinal study will be carried out in strict response to the STOP safety concept of the Safety, Security, Health and Environment administrative department of ETH.

Description

Inclusion Criteria:

• ETH employee or ETH student and their family members living in the same household at the start of the study
• Between 18 and 64 years of age at the start of the study
• Signed informed consent

Exclusion Criteria:

• Age over 64 years at the start of the study
• In quarantine or self-confinement at the start of the study

• Active COVID-19 infection at the start of the study:

  • Diagnosed with a laboratory test
  • Suspected based on typical symptoms such as fever (>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste

• The following medical condition

  • With continuous steroid therapy/ chemotherapy/immunsuppressive therapy
  • In treatment for cancer
  • With severe autoimmune disease

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
ETH cohort; employees or students at ETH Zurich, Switzerland

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens	12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens	12 months
the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection	12 months
the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections	12 months

Collaborators and Investigators

• Sponsor: Goldhahn Jörg
• Investigators: Study Chair: Jörg Goldhahn, MD, ETH Zurich; Study Director: Susanne Ulbrich, Prof. Dr., ETH Zurich; Study Director: Markus Stoffel, Prof. Dr., ETH Zurich

Publications and helpful links

Helpful Links

• study information and call

Study record dates

Study Major Dates

• Study Start (Actual): April 27, 2020
• Primary Completion (Actual): February 4, 2022
• Study Completion (Actual): February 4, 2022

Study Registration Dates

• First Submitted: May 5, 2020
• First Submitted That Met QC Criteria: May 5, 2020
• First Posted (Actual): May 6, 2020

Study Record Updates

• Last Update Posted (Estimate): February 23, 2023
• Last Update Submitted That Met QC Criteria: February 22, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Virus Diseases
• Other Study ID Numbers: 20-05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No